Ximing T. Xu - Publications

Heterogeneity in primary gastrointestinal DLBCL: from clinical management to molecular mechanisms and treatment strategies.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 20, 2026

Modularly designed hybrid vesicles as dual-adjuvant nanovaccines for cancer immunotherapy.

Journal: Biomaterials

Published: February 05, 2026

Extracellular matrix stiffness in hepatocellular carcinoma: mechanisms and targeted therapeutic strategies.

Journal: Frontiers in immunology

Published: December 23, 2025

Disrupting KAT8 Liquid-Liquid Phase Separation with Hybrid Vesicle-Liposome Platform for Enhanced PD-L1 Blockade Treatment.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: November 26, 2025

Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis.

Journal: Human vaccines & immunotherapeutics

Published: October 13, 2025

Matrix stiffening-driven hepatocellular carcinoma progression through OASL-mediated cGAS-STING repression and subsequent macrophage activation.

Journal: International immunopharmacology

Published: October 11, 2025

ROS-responsive cellular vesicles with ferroptosis-targeting siACMSD delivery for acute kidney injury therapy.

Journal: Theranostics

Published: June 16, 2025

A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers.

Journal: Human vaccines & immunotherapeutics

Published: June 12, 2025

Genetically engineered Magnesium/Manganese nanoparticles for cancer radioimmunotherapy.

Journal: Journal of nanobiotechnology

Published: May 06, 2025

PRMT5 inhibits the ferroptosis of hepatocellular carcinoma via regulating RBM15/FTH1 signaling.

Journal: American journal of cancer research

Published: May 04, 2025

Nanodelivery of Y-27632 by RGD-modified liposome enhances radioimmunotherapy of hepatocellular carcinoma via tumor microenvironment matrix stiffness reprogramming.

Journal: Theranostics

Published: April 01, 2025

Immune Cellular Patterns Predicting Lymph Node Status Helps Personalized Management of Stage T1 Esophageal Squamous Cell Carcinoma.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: March 17, 2025